Introduction: In Senegal, the decentralization of Health Care Centers has contributed significantly to the intensification of antiretroviral treatment. However, Care providers are still facing the treatment optimizing challenge. Objectives: To determine the prevalence of virologic failures of PLHIV monitored in a decentralized Health care center and to determine associated factors. Patients and Methods: This is a cross-sectional descriptive and analytical study of PLHIV, aged 18 years and over, on first-line treatment, monitored onsite from February 1st to December 31st, 2018. A data collection form was completed from medical records (clinical, immuno-virologic and evolutionary). Any VL > 1000 cp/ml after 6 months of antiretroviral therapy (ART) was considered as virologic failure. Data were captured and analysed using the EPI INFO 2002software. Chi-square test and the Fisher test were used to compare the proportions; a value of p ≤ 0.05 was considered significant. Results: 331 patients were treated with HIV-1 profile in 89% of cases. A proportion of 55% was married and 97% came from rural areas. 80% were either not or poorly educated. The median of age was 44 ± 11 years with a F/M ratio of 3.4. At baseline, 56% were symptomatic at stage 3 or 4 of WHO. They had severe immunosuppression with a median CD4 count of 217 ± 187 cells/mm 3 , the viral load was detectable in half of the patients with a median VL of 97,000 cp/ml ± 70,569. The antiretroviral regimen combined 2 NRTIs with 1 NNRTI in 88% of cases. The median of follow-up was estimated at 60 How to cite this paper: ± 43 months. The prevalence of virologic failure was 19%. This prevalence was associated with age less than 25 years (p = 0.04), late diagnosis (CD4 at baseline less than 200 cel/mm 3 (p = 0.002), stage 3 or 4 WHO (p = 0.04) High viral load greater than 10,000 (p = 0.04) at baseline. Conclusion: These results suggest making the new therapeutic classes accessible for first-line treatment.
Introduction
The advent of triple antiretroviral therapy has revolutionized the management of HIV infection by providing lasting suppression of viral replication. This led to a drastic reduction in HIV-related morbidity and mortality, a clear improvement in expectation and quality of life at the individual level, a decrease in the incidence of the disease in regions with good treatment coverage at the community level [1] [2] [3] .
There is solid evidence that the increasing improvement of the quality in HIV treatment will save the lives of millions of people, protect them from the risk of infection and save financial resources, in view to eradicate the AIDS epidemic [4] [5] .
The Senegalese Antiretroviral Drug Access Initiative (ISAARV) has been initiated since 1998. It followed the various WHO recommendations for antiretroviral treatment (ART). Decentralization, which began in the 2000s, has led to a significant increase in the number of PLHIV on ART. The number of patients under ART increased from 1855 in 2004 to 23202 in 2017 with a proportion of 62% living in rural areas [6] [7] . However, despite all efforts to intensify treatment, practitioners still face some challenges within the management of HIV infection including under-optimization of ART due to the fact that coverage of viral infection is still low on the one hand [7] but also the relatively high prevalence of therapeutic failures [8] [9] [10] . Also, there are few studies on the evaluation of ART in patients treated in a decentralized setting in Senegal [9] [10] [11] .
Our study is, therefore, carried out in this context, in one of the largest decentralized health care facilities. The objective of the study was to study the prevalence of virologic failure of first-line antiretroviral therapy for PLHIV treated at the Roi Baudouin public health care center and to determine the associated factors. 
Patients and Methods

Results
Epidemiological Aspects
Therapeutic Aspects
The antiretroviral regimen combined 2 nucleoside reverse transcriptase inhibitor 
Evolutionary Aspects
The mean duration of follow-up was 60 months ± 43. Compliance was rated as good in 90% of cases. The prevalence of treatment failure was 19% (62 patients).
The time to onset of virologic failure was at M12 (Month 12) in 40% of cases, 19% of virologic failures occurred at M24 follow-up and 27% at M36. The virologic failure involved 57 patients with NNRTI and 5 patients with PI. The prevalence of virologic failure was higher in younger patients < 25 years of age (35% versus 18%) p = 0.04, but also in those with severe immunosuppression with CD4 < 200 cell/mm 3 (25% versus 13%) p = 0.002. Virologic failure was also associated with advanced-stage disease (WHO stage 3 or stage 4) at baseline (30% versus 14%) p = 0.04 and high viral load at ART initiation (21% versus 7%) p = 0.002. However, the association was not significant between treatment failure and sex (p = 0.47) and level of education (p = 0.48) ( Table 3 ). [16] .
The median age in our series was 44; like what was found in Togo [17] ; meanwhile, it is much higher than the results found in Burkina Faso [18] . The low level of school education in our series is comparable to the findings in Mozambique [19] .
Clinically, our study revealed that most of patients requesting treatment were at an advanced stage of the disease with opportunistic infections. This late recourse to treatment is a common issue within the monitoring of HIV infection
in several African countries [20] [21] [22] .
At paraclinical level, the low level of CD4 lymphocytes counts also justified the late detection of HIV infection [12] [18] [22] .
With regards to treatment, the classic association of 2NRTI and 1NNRTI was the standard in our study in 89% of cases. This choice is consistent with WHO recommendations [23] and is based primarily on cost but also on the need to maintain generic LPV/r stocks for second-line treatment of HIV-1 infection in resource-limited countries.
Virologically, viral load quantification was used to evaluate the antiretroviral response [23] and a virological failure prevalence of 19% was determined. This prevalence was lower than those in the subregion, namely in Togo [17] , Burkina
Faso [18] and Cameroon [14] . On the other hand, a smaller prevalence has been described in Ethiopia [24] , Nigeria [25] , South Africa [26] and Uganda [27] with a prevalence of 14.7%, 13.7%, 13.7% and 11.3%, respectively.
In our series, failure was not associated with sex, unlike in Burkina [18] , Tanzania [28] and Uganda [29] . This difference in vulnerability could be explained by a pharmacological difference based on sex [30] but also the low hospitalization of men [18] .
However, our study has shown an association between virologic failure and young age. This is a confirmation of what was found in several studies [12] [24]
[31] [32] .
Several factors were associated with failure in adolescents. In addition to poor compliance [10] [24] and long exposure [33] , the inadequacy of galenic forms has also been reported [34] . It is, therefore, necessary to strengthen therapeutic education sessions for better adherence of adolescents but also to conduct studies aiming at clarifying the biological causes of high rates of virologic failure in young subjects [12] .
Likewise, as described in several studies [18] We could not document the mutations of resistance associated with therapeutic failures, like in the study of Dioura [9] . This is a limitation in our study and can be explained by the limited accessibility to these tests only performed in HIV treatment reference centers. Thus, it would be relevant to conduct an epidemiological surveillance of resistance by performing genotyping tests to justify the choice of effective molecules for the treatment of HIV infection. However, special attention should be paid to our study. In fact, the sub-optimal therapeutic response addressed in our study with a high prevalence of virologic failure is an appeal to urgently make available new high-barrier therapeutic classes namely integrase inhibitors to improve the quality of first-line ART in HIV-infected patients. Moreover, the efficacy of integrase inhibitors as first-line treatment compared to NRTI and PI has been described in several studies [36] [37] [38] [39] .
This led to the recommendations formulated by WHO and UNAIDS to support the use of Dolutegravir-based protocols as first-line treatment in HIV-infected patients [40] [41] . Applying these new recommendations in Senegal could help optimize ART and monitor treatment failures effectively [42] .
Conclusion
Our study is one among the first conducted in a decentralized setting. It showed a virological failure prevalence of 19%. This prevalence was associated with young age, but also with late diagnosis. The results of our study suggest making available the genotyping tests in decentralized setting to better adapt the second-line therapeutic choices. Thus, it is urgent to make the integrase inhibitors with a strong genetic barrier available in Senegal to improve the quality of HIV infection monitoring. Implementing these measures is crucial for achieving the UNAIDS 90-90-90 goals.
